Summary of Aptamer-MB pull down experiments using mass spectrometry detection.

Table 2: Summary of Aptamer-MB pull down experiments using mass spectrometry detection.

Trial 1: Buffer + 100 µl of Aptamer-MBs
Target	AA-3	AA-3	GHRP-6	GHRP-6
Aptamer	AS-28F	AU-23F	G6S-16F	G6U-18R
Detection	+	+	-	low +
Trial 2: Buffer + 500 µl of Aptamer-MBs
Target	AA-3	AA-3	GHRP-6	GHRP-6
Aptamer	AS-28F	AU-23F	G6S-16F	G6U-18R
Detection	+	+	+	-
Trial 3: Serum + 500 µl of Aptamer-MBs
Target	AA-3	AA-3	GHRP-6	GHRP-6
Aptamer	AAS-28F	AAU-23F	G6S-16F	G6U-18R
Detection	+	+	+	-
Trial 4: Urine + 500 µl of Aptamer-MBs
Target	AA-3	AA-3	GHRP-6	GHRP-6
Aptamer	AAS-28F	AAU-23F	G6S-16F	G6U-18R
Detection	+	+	+	+

Notes: (+): Successful detection of the subject peptide by MS at any level; (-): No target peptide detection by MS and (+ low): Barely perceptible peak for the subject peptide. Negative control results employing streptavidin (SAv)-MBs without aptamers are not shown in the table, but were negative (i.e., failed to show any evidence of AA-3 or GHRP-6 adhering to SAv-MBs by MS when buffer was spiked with 100 µg of AA-3 or GHRP-6 and the pull down assay was conducted without biotinylated aptamers on the SAv-MBs).